KAYTUS
23.5.2024 09:40:31 CEST | Business Wire | Press release
KAYTUS, a leading IT infrastructure provider, launched at ISC High Performance 2024 the K22V2, a multi-node server with exceptional compute density and energy efficiency. The K22V2 integrates two independent hot-swap single-socket compute nodes in a 2U form factor. Each node supports either a 4th Gen AMD EPYC™ 9004 series processor with 12 DDR5 RDIMMs (4800MHz) or a 5th Gen Intel® Xeon® processor with eight DDR5 RDIMMs (5600MHz), offering flexible storage and I/O configurations. Each node also supports 6 SATA/NVMe SSDs or 8 E1.S SSDs, along with 4 PCIe 5.0 slots and one OCP NIC 3.0. This makes it an optimal choice for compute-intensive applications, suitable for customers seeking both high compute density and cooling efficiency.
Advanced 1U Computing Density Enhanced by 2U Cooling and O&M Efficiency
Focused on energy efficiency, K22V2 is fitted to accommodate two single-socket nodes within a 2U space, in a horizontal layout. Each node functions as an autonomous server system, enabling independent hot maintenance with plug-and-play support to minimize disruption, thus significantly enhancing O&M efficiency. This design is advantageous for opting for 2U high efficiency heatsinks. A 2U heatsink, due to its effective utilization of vertical space, features a length merely one-fifth that of a 1U heatsink, facilitating a more efficient server layout. Furthermore, the air flow resistance of a 1U heatsink is four times that of a 2U counterpart at the same air volume (50 CFM), necessitating fans with higher power.
According to testing data, the cooling efficiency of the server in a 2U space is superior when two single-socket nodes are horizontally arranged in parallel compared to when two 1U single-socket nodes are vertically stacked. The K22V2 demonstrates 40% better cooling efficiency compared to two standard 1U rack servers under the same computing conditions, while also reducing power consumption by up to 8%.
New pioneering architecture delivers better cost performance efficiency
The K22V2 server features a streamlined modular design where two nodes share the chassis, backplane, fan, and PSU, providing significant L6 cost advantages compared to products with two independent nodes. This pioneering architecture is optimized for high-performance single-socket processors and addresses the issue of high migration costs associated with a single server failure impacting multiple tasks. Consequently, the K22V2 is versatile, supporting a wide range of typical applications from computing to big data, and is ideal for scenarios requiring demanding computing density and cooling efficiency. Additionally, it offers users more convenient O&M.
System Overview |
KAYTUS K22V2 Multi-node server (Side by side) |
Normal 2x 1U servers (Stack up) |
System Configuration |
||
System depth |
880 mm |
850 mm |
CPU Heatsink |
2U EVAC |
1U EVAC |
Fan |
6056*6 |
4056*8 |
CPU Power (EGS) |
300W |
300W |
CPU Core Count |
104 |
208 |
Thermal Evaluation Result |
||
Fan Duty |
50% |
70% |
Total Fan Power |
83.6W |
268.8W |
Fan Power/Per CPU |
41.8W |
67.2W |
Note |
All thermal evaluations are based on conditions of a 35°C ambient temperature, sea level, and a normally operating fan. |
|
About KAYTUS
KAYTUS is a leading provider of IT infrastructure solutions, delivering a diverse range of cutting-edge, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523837473/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom